Amgen Gets High Court Review in Repatha Patent Fight with Sanofi

US Supreme Court agrees to hear appeal by Amgen, will consider reviving two patents for Repatha cholesterol drug in fight with Sanofi and Regeneron over their rival Praluent medicine.

• Justices will review federal appeals court decision that rejected Amgen’s suit seeking to get Praluent taken off market
• Case being closely watched in biotechnology and pharmaceutical industries to clarify whether and how patents can be granted for new group of antibodies
• Justice Department had recommended Supreme Court reject appeal
• Amgen patents, which would expire in August 2028, are related to antibodies called PCSK9 inhibitors, which help reduce LDL cholesterol levels
• Case is Amgen v. Sanofi, 21-757

To contact the reporter on this story:
Greg Stohr in Washington at gstohr@bloomberg.net

To contact the editor responsible for this story:
Elizabeth Wasserman at ewasserman2@bloomberg.net

© 2022 Bloomberg L.P. All rights reserved. Used with permission.